Carl H. June
Auto-generated profile, based on publicly available information

Carl H. June

University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2011 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
DPDavid L. Porter
David L. Porter
BLBruce L. Levine
Bruce L. Levine
MKMichael Kalos
Michael Kalos
ABAdam Bagg
Adam Bagg
CJCarl H. June
Carl H. June
We designed a lentiviral vector expressing a chimeric antigen receptor with specificity for the B-cell antigen CD19, coupled with CD137 (a costimulatory receptor in T cells [4-1BB]) and CD3-zeta (a signal-transduction component of the T-cell antigen receptor) signaling domains. A low dose (approximately 1.5×105 cells per kilogram of body weight) of autologous chimeric antigen receptor–modified T cells reinfused into a patient with refractory chronic lymphocytic leukemia (CLL) expanded to a level that was more than 1000 times as high as the initial engraftment level in vivo, with delayed development of the tumor lysis syndrome and with complete remission. Apart from the tumor lysis syndrome, the only other grade 3/4 toxic effect related to chimeric antigen receptor T cells was lymphopenia. Engineered cells persisted at high levels for 6 months in the blood and bone marrow and continued to express the chimeric antigen receptor. A specific immune response was detected in the bone marrow, accompanied by loss of normal B cells and leukemia cells that express CD19. Remission was ongoing 10 months after treatment. Hypogammaglobulinemia was an expected chronic toxic effect.

18 April 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SGStephan A. Grupp
Stephan A. Grupp
MKMichael Kalos
Michael Kalos
DBDavid Barrett
David Barrett
RARichard Aplenc
Richard Aplenc
DPDavid L. Porter
David L. Porter
CJCarl H. June
Carl H. June
Chimeric antigen receptor–modified T cells with specificity for CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL). It remains to be established whether chimeric antigen receptor T cells have clinical activity in acute lymphoblastic leukemia (ALL). Two children with relapsed and refractory pre–B-cell ALL received infusions of T cells transduced with anti-CD19 antibody and a T-cell signaling molecule (CTL019 chimeric antigen receptor T cells), at a dose of 1.4×106 to 1.2×107 CTL019 cells per kilogram of body weight. In both patients, CTL019 T cells expanded to a level that was more than 1000 times as high as the initial engraftment level, and the cells were identified in bone marrow. In addition, the chimeric antigen receptor T cells were observed in the cerebrospinal fluid (CSF), where they persisted at high levels for at least 6 months. Eight grade 3 or 4 adverse events were noted. The cytokine-release syndrome and B-cell aplasia developed in both patients. In one child, the cytokine-release syndrome was severe; cytokine blockade with etanercept and tocilizumab was effective in reversing the syndrome and did not prevent expansion of chimeric antigen receptor T cells or reduce antileukemic efficacy. Complete remission was observed in both patients and is ongoing in one patient at 11 months after treatment. The other patient had a relapse, with blast cells that no longer expressed CD19, approximately 2 months after treatment. Chimeric antigen receptor–modified T cells are capable of killing even aggressive, treatment-refractory acute leukemia cells in vivo. The emergence of tumor cells that no longer express the target indicates a need to target other molecules in addition to CD19 in some patients with ALL.

3 December 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
DFDavid C. Fajgenbaum
David C. Fajgenbaum
CJCarl H. June
Carl H. June
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has reminded us of the critical role of an effective host immune response and the devastating effect of immune dysregulation. This year marks 10 years since the first description of a cytokine storm that developed after chimeric antigen receptor (CAR) T-cell therapy1 and 27 years since the term was first used in the literature to describe the engraftment syndrome of acute graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation.2 The term “cytokine release syndrome” was coined to describe a similar syndrome after infusion of muromonab-CD3 (OKT3).3 Cytokine storm and cytokine release syndrome are life-threatening systemic inflammatory syndromes involving elevated levels of circulating cytokines and immune-cell hyperactivation that can be triggered by various therapies, pathogens, cancers, autoimmune conditions, and monogenic disorders.

23 March 2018 in Science
Verified
Journal Article
Closed access
PDF file
CJCarl H. June
Carl H. June
RORoddy S. O’cOnnor
Roddy S. O’cOnnor
OKOmkar U. Kawalekar
Omkar U. Kawalekar
SGSaba Ghassemi
Saba Ghassemi
MMMichael C. Milone
Michael C. Milone
Adoptive T cell transfer (ACT) is a new area of transfusion medicine involving the infusion of lymphocytes to mediate antitumor, antiviral, or anti-inflammatory effects. The field has rapidly advanced from a promising form of immuno-oncology in preclinical models to the recent commercial approvals of chimeric antigen receptor (CAR) T cells to treat leukemia and lymphoma. This Review describes opportunities and challenges for entering mainstream oncology that presently face the CAR T field, with a focus on the challenges that have emerged over the past several years.

8 January 2019 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
RRRachel S. Riley
Rachel S. Riley
CJCarl H. June
Carl H. June
RLRobert Langer
Robert Langer
MMMichael Mitchell
Michael Mitchell

5 July 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
CJCarl H. June
Carl H. June
MSMichel Sadelain
Michel Sadelain
This review addresses T-cell engineering and synthetic immunity, with a focus on producing durable remissions in patients with treatment-refractory tumors. Toxic effects of chimeric antigen receptor therapies include cytokine release syndrome and neurologic dysfunction.